Malignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific InterventionsGlobeNewsWire • 06/07/24
Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 05/30/24
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office BuildingsBusiness Wire • 05/21/24
How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash?Forbes • 05/15/24
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 CongressBusiness Wire • 05/14/24
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common StockBusiness Wire • 05/13/24
Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 04/30/24
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 04/30/24
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsBusiness Wire • 04/23/24
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaBusiness Wire • 04/01/24
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast AsiaGlobeNewsWire • 04/01/24